Neurology

11.
Neuro-oncology
11.2.
Primary Brain Tumors
11.2.1.
Gliomas
11.2.1.1.
Astrocytomas
11.2.1.1.1.
Pilocytic Astrocytoma
11.2.1.1.1.1.
Pathology
11.2.1.1.1.2.
Clinical Features
11.2.1.1.1.3.
Imaging
11.2.1.1.1.4.
Management
11.2.1.1.2.
Diffuse Astrocytoma
11.2.1.1.2.1.
IDH-Mutant
11.2.1.1.2.2.
IDH-Wildtype
11.2.1.1.2.3.
Pathology
11.2.1.1.2.4.
Clinical Features
11.2.1.1.2.5.
Management
11.2.1.1.3.
Anaplastic Astrocytoma
11.2.1.1.3.1.
Pathology
11.2.1.1.3.2.
Clinical Features
11.2.1.1.3.3.
Management
11.2.1.1.4.
Glioblastoma
11.2.1.1.4.1.
Pathology
11.2.1.1.4.2.
Molecular Markers
11.2.1.1.4.2.1.
MGMT Methylation
11.2.1.1.4.2.2.
IDH Status
11.2.1.1.4.2.3.
1p/19q Codeletion
11.2.1.1.4.3.
Clinical Features
11.2.1.1.4.4.
Imaging
11.2.1.1.4.5.
Management
11.2.1.1.4.5.1.
Surgery
11.2.1.1.4.5.2.
Radiation Therapy
11.2.1.1.4.5.3.
Chemotherapy
11.2.1.1.4.5.4.
Targeted Therapy
11.2.1.1.4.6.
Prognosis
11.2.1.3.
Ependymomas
11.2.1.3.1.
Classification
11.2.1.3.3.
Management
11.2.1.4.
Mixed Gliomas
11.2.1.4.1.
Oligoastrocytoma
11.2.1.4.3.
Management
11.2.3.
Pituitary Tumors
11.2.3.1.
Pituitary Adenomas
11.2.3.1.3.
Clinical Features
11.2.3.1.3.1.
Hormonal Effects
11.2.3.1.3.2.
Mass Effects
11.2.3.1.4.
Diagnosis
11.2.3.1.4.1.
Hormonal Testing
11.2.3.1.4.2.
Imaging
11.2.3.1.5.
Management
11.2.3.1.5.1.
Medical Therapy
11.2.3.1.5.2.
Surgical Therapy
11.2.3.1.5.3.
Radiation Therapy
11.2.3.2.
Craniopharyngiomas
11.2.3.2.1.
Pathology
11.2.3.2.3.
Management

Previous

10. Infections of the Nervous System

Go to top

Next

12. Disorders of the Peripheral Nervous System